ipt date: (02/14/2005		09 10 045 /-09 AU
TOTAL STATE		u c i	Approved for use through 07/31/2006. OMB 0651-003 Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCI
Under the Par	perwork Reduction Act of 1995, no	persons are required to respond to a co	Illection of information unless it displays a valid OMB control number
T. B	.1	Application Number	09/709,045
TRANCE TR	ANSMITTAL	Filing Date	November 10, 2000
	FORM	First Named Inventor	M. Rigdon Lentz
N. A.		Art Unit	1647
(to be used for	au correspondence after initial filin	Examiner Name	Lorraine Spector
	Pages in This Submission	Attorney Docket Number	LEN 102
		ENCLOSURES (Check all	I that apply)
7			After Alloway ce Communication to TC
✓ Fee Trans	smittal Form	Drawing(s)	Appeal Communication to Board
L ⊢ F€	ee Attached	Licensing-related Papers	of Appleals and Interferences
Amendme	ent/Reply	Petition	Appeal Communication to TC Appeal Notice, Brief, Reply Brief)
	N.	Petition to Convert to a Provisional Application	Proprietary Information
Af	fter Final	Power of Attorney, Revocation	on Server Lawre
Af	ffidavits/declaration(s)	Change of Correspondence	Other Enclosure(s) (please Identify
Extension	n of Time Request	Terminal Disclaimer	below):
Express /	Abandonment Request	Request for Refund	one (1) page of PTO-1449; five (5) references; return postcard
	on Disclosure Statement	CD, Number of CD(s)	<u>/</u>
[▼ Informatio	on Disclosure Statement	Landscape Table op	, D
	Copy of Priority	Remarks	
Documen	``	X	
Incomple	Missing Parts/ te Application		
R	eply to Missing Parts nder 37 CFR 1.52 or 1.53		
	SIGNAT	URE OF APPLICANT, ATTO	DRNEY, OR AGENT
Firm Name	Pabst Patent Grou		
Signature	N.11.60		
Printed name	Tiffany B. Salmon		
Date			Reg. No. 55,589
	February I 2005		
	CE	RTIFICATE OF TRANSMISS	SION/MAILING
	and their conference in the	ing facsimile transmitted to the USP	TO or deposited with the United States Postal Service with or Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
sufficient postage	e as first class mail in an enve	//	3.
I hereby certify the sufficient postage the date shown be Signature	e as first class mail in an enve	A hana	_
sufficient postage the date shown b	e as first class mail in an enve	A. Bera	Date February //, 2005

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 02/14/2005

09708045120GAU: 1647

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number Complete if Known Effective on 12/08/2004 oursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). 09/709,045 **Application Number** TRANSMIT Filing Date November 10, 2000 For FY 2005 M. Rigdon Lentz First Named Inventor FEB L. Spector **Examiner Name** Applicant clams small entity status. See 37 CFR 1.27 1647 Art Unit (\$) 180.00ADEMA TOTAL AMOUNT OF PAYMENT **LEN 102** Attorney Docket No METHOD OF PAYMENT (check all that apply) Check Money Order None Other (please identify): Credit Card ✓ Deposit Account Deposit Account Number: 50-3129 Deposit Account Name: Pabst Patent Froup LLP For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) of underpayments of fee(s) Credit any overpayments, under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card information should not be included on his form. Provide credit card information and authorization on PTO-2038. **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES EXAMINATION FEES **Small Entity Small Entity Small Entity** Fees Paid (\$) **Application Type** Fee (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) 200 300 500 Utility 150 250 100 200 100 100 130 65 Design 50 80 200 160 Plant 300 100 300 500 600 Reissue 150 300 200 0 0 Provisional 100 0 2. EXCESS CLAIM FEES **Small Entity** Fee (\$) Fee (\$) **Fee Description** Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent 50 25 100 Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent 200 180 Multiple dependent claims Fee Paid (\$) Multiple Dependent Claims **Total Claims** Extra Claims Fee (\$ 0.00 Fee Paid (\$) =0<u>.00</u> Fee (\$) <u>14</u> - 20 or HP = HP = highest number of total claims paid for, if greater than 20 Fee Paid (\$) Indep. Claims **Extra Claims** <u> Çee (\$)</u> - 3 or HP = 0.00 HP = highest number of independent claims paid for, if greater than 3 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(§ Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$) **Total Sheets** (round up to a whole number) x - 100 = Fees Paid (\$) 4. OTHER FEE(S) Non-English Specification, \$130 fee (no small entity discount) 188,00 Other: Information Disclosure Statement SUBMITTED BY Registration No. Telephone (404) 879-2153 55.589 Signature (Attorney/Agent) Date February 11, 2005 Name (Print//ype) Tiffany B. Salmon This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete,

including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS DDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

M. Rigdon Lentz

Serial No .:

09/709,045

Art Unit:

1647

Filed:

November 10, 2000

Examiner:

Lorraine Spector

For:

METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DESCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449, and copies of the five (5) documents cited therein.

The Commissioner is hereby authorized to charge \$180.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first Office Action on the merits under 37 L.F.R. §1.97(c). It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any feet to Deposit Account No. 50-3129.

U.S. Patents

/CMW/

Number 5,932,704 Issue Date 08-03-1999 Patentee Jubinsky Class/Subclass 530/388.22

02/16/2005 BARAHA1 00000007 503129 09709045

01 FC:180#

180.00 DA 45054471v1

1

LEN 102 077829/00006 U.S.S.N.: 09/709,045 Filed: November 10, 2000

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Foreign Documents

Nuraber	Publication Date	<u>Patentee</u>	Country
0 184 040	11-06-1986	Anisa Medical Inc.	E X
02045004	02-15-1990	Ube Industries	JP
WO 96/18666	06-06-1996	Sanitaria Scaligera S.P.A.	PCT

Publications

GERAIN, et al., "Systemic release of soluble TNF receptors after high-dose TNG in isolated limb perfusion" *Cytokine* 9(12):1034-1042 (1997).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Tiffany B. Salmon Reg. No. 55,589

Dated: February, 2005

PABST PAZENT GROUP LLP 400 Colory Square, Suite 1200 1201 Pachtree Street Atlanta, Georgia 30361 (404) 879-2153 (Telephone) (404) 879-2160 (Fax)

09709045 ~ GAU: 1647
PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		Substitute fo	r form 1449	A/PTO	Con	nplete if Known	
FI	⊥	ST.	ATEME	TION DISCLOSURE NT BY APPLICANT any sheets as necessary)	Application Number	09/709,045	
19	1	Ħ			Filing Date	November 10, 2000	
FI		.8			First Named Inventor	M. Rigdon Lentz	
Z.G.	BADEMA				Group Art Unit	1647	
`	ANDER	•			Examiner Name	Lorraine Spector	
	Sheet	1	of	2	Attorney Docket Number	LEN 102	

U.S. PATENT DOCUMENTS							
Examiner Initials*		US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
;		Number Kind Code ² (if known)					
/CMW/		5,932,704	Jubinsky	08-03-1999			

				F	OREIGN PATENT DOCUMENT	rs .			
Examiner Initials*	Cite No. ¹			Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
		Office.3	Number⁴	Kind Code⁵ (if known)					
/CMW/		EP	0 184 040	_	Anisa Medical Inc.	06-11-1986			
/CMW/		JP	02045064		Ube Industries	02-15-1990		T	
/CMW/		PCT	WO 96/16666		Santaria Scaligera S.P.A.	06-06-1996			
		 		<u> </u>				┼	
								<u> </u>	
								 	
						-		┼──	

Examiner's	101 1 32 331 1 1/	Date Considered	
Signature	/Cherie M. Woodward/		11700/2011

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

> The PTO did not receive the following listed_Item(s)

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

O9709045 ~ GAU: 1647
PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

			Act of 1995, r form 1449		tion of information unless it contains a valid OMB	nplete if Known	
6	PECTO	STA	TEME	TION DISCLOSURE NT BY APPLICANT ny sheets as necessary)	Application Number	09/709,045	
	8 1 1 2005		•	•	Filing Date	November 10, 2000	
₩.		7			First Named Inventor	M. Rigdon Lentz	
ELTER.	ر الأنتا	•			Group Art Unit	1647	
VZ.	PADEMARK				Examiner Name	Lorraine Spector	
	Sheet	2	of	2	Attorney Docket Number	LEN 102	

	OTHER ART NON PATENT LITERATURE DOCUMENTS						
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²				
/CMW/	· _	GERAIN, et al., "Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion" <i>Cytokine</i> 9(12):1034-1042 (1997).					
		,					
	.		<u>.</u>				
			-				
	.,.						

	the state of the s	
Examiner's Signature	/Cherie M. Woodward/	Date Considered 11/08/2011

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.